Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer
Ningning Cheng(Tongji University), Caicun Zhou(Tongji University), Qi Wang(Jilin University), Xuefei Li(Harbin Medical University), Jiayu Li(Tongji University), Chao Zhao(Tongji University), Weijing Cai(Hebei Medical University), Mingchuan Zhao(Tongji University), Shengxiang Ren(Tongji University), Xiaoxia Chen(Shanghai Pulmonary Hospital), Yishi Zhang(Tongji University)
Cited by 82
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
|Nature|2012|745